RxDoctor Payments Data

Imran Punekar, MD

Interventional Pain Medicine · New York, NYNPI 1104354935

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by MML US, Inc. at 27.0% of the total. Reporting peaked in 2023 at $5,213 and has fallen 80.9% since, to $995 in 2025.

$9,363in general payments, 2019–2025

Across 111 payments — averaging $84.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MML US, Inc.$3K
  • Relievant Medsystems, Inc.$2K
  • Medtronic$1K
  • Vertos Medical, Inc.$1K
  • Boston Scientific$613
  • Choice Spine, LLC$399
  • plus $2K from 10 others

What the payments were for

  • Travel & lodging$8019%
  • Food & beverage$8,56291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,363 in reported general payments places this provider in the 70th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$8,527
Medicare patients
62
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional pain medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →